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ABSTRACT
Robot-assisted laparoscopic prostatectomy (RALP) is a potentially curative surgical
intervention for men with clinically localized prostate cancer. Although RALP can provide
excellent oncological outcomes, it is also associated with detrimental effects to functional
outcomes, particularly urinary continence, which negatively impact post-operative
quality of life. The purpose of this study is to identify the degree to which pre-operative
patient factors, tumor characteristics, and surgical technique influenced the postoperative return of urinary continence in men undergoing RALP performed by a single
surgeon for the treatment of clinically localized prostate cancer. We analyzed 182
consecutive patients with clinically localized prostate cancer who were treated with RALP
between April 2013 and September 2020. A retrospective chart review was performed to
evaluate pre-operative patient and tumor characteristics, as well as post-operative
urinary continence. Achievement of urinary continence was defined as wearing no pads
or an occasional security pad by patient-reported daily pad usage within 3 (early) and 12
months (late) after RALP. Postoperatively, 68 (37.3%) and 120 (78.9%) men achieved early
and late recovery of continence, respectively. Multivariate logistic regression analyses
revealed that Retzius sparing approach (OR 2.995; 95% CI 1.265 – 7.089; p = 0.013) and
lower BMI (OR 0.823; 95% CI 0.823 – 0.988; p = 0.027) were associated with continence
at 3 months post-operatively, while longer pre-operative membranous urethral length
(OR 1.205; 95% CI 1.003 – 1.448; p = 0.047) and younger age (OR 0.907; 95% CI 0.824 –
0.998; p = 0.044) were associated with continence at 12 months post-operatively.
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1
BACKGROUND

Prostate Cancer: Epidemiology and Treatment
Prostate cancer continues to be the most common non-skin malignancy and the
second-leading cause of cancer deaths among men in the United States. There will be an
estimated 191,930 new cases diagnosed in 2020, representing 21% of new cancer cases
in men, and over 33,000 deaths [1]. Fortunately, the majority of cases are slow-growing
and low grade with limited aggressiveness. Consequently, the overall 5-year survival rate
in the United States is greater than 98%, and the lifetime risk of death from prostate
cancer is less than 3% [2]. The true prevalence of prostate cancer is likely substantially
higher than reported based on evidence from autopsy studies [3, 4].
The primary risk factors for developing prostate cancer are age, race, and family
history of the disease. It is primarily a disease of older men, with 99% of all prostate
cancers occurring in men over the age of 50. Incidence is also known to be associated with
hereditary and geographic factors previously described as ‘race.’ In the United States, the
rate of new cases per 100,00 in 2017 was 163.8, 96.7, 80.9, and 54.9 among White, Black,
Hispanic, and Asian/Pacific Islander men, respectively [5]. Other risk factors include
obesity, hypertension, elevated testosterone levels, and certain environmental
exposures.
In recent decades, an increasing number of cases have been diagnosed at earlier
clinical stages, due primarily to the widespread adoption of prostate-specific antigen
(PSA)-based testing [6]. This so-called “stage migration” has significant implications for
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treatment counseling. First, a larger proportion of newly diagnosed tumors are confined
to the prostate, making them more amenable to localized therapies aimed at removing
malignant tissue. Second, a greater number of young, otherwise healthy men are
receiving the diagnosis of prostate cancer. This population may have different goals and
expectations regarding post-operative quality of life outcomes, namely the preservation
of urinary and erectile function, compared to the older cohort of the pre-PSA era.
Patients with localized prostate cancer (clinical stage T1-T2, N0 or NX, M0 or MX)
are stratified into risk categories to guide treatment decisions based on clinical stage, PSA,
Grade Group, amount of cancer on biopsy (i.e., number of cores involved, maximum
involvement of any single core), PSA density, and diagnostic imaging. Current primary
treatment modalities include active surveillance (PSA testing, digital rectal exams,
surveillance biopsies), external beam radiation therapy (RT), ablative procedures
(cryoablation, high-intensity ultrasound, etc.), and radical prostatectomy (RP). According
to current AUA guidelines, Level A evidence (strong recommendation) supports the use
of RP for patients with intermediate- to high-risk disease. Level B evidence (conditional
recommendation) supports its use in low-risk disease in patients who have a high
probability of progression on active surveillance, though clinicians should recommend
active surveillance for most low-risk localized prostate cancer patients. These conclusions
are based on three notable prospective randomized controlled trials investigating the
long-term mortality and functional outcomes after RP compared to other interventions.
The Scandinavian Prostate Cancer Study Group number 4 (SPCG-4) randomized
695 men with localized prostate cancer to treatment with RP or watchful waiting between

3
1989 and 1999. The study found a reduced risk of all-cause and prostate cancer-specific
death, a lower rate of prostate cancer metastasis, and less use of palliative androgendeprivation therapy in the RP group after a median follow-up time of 13.4 years. These
effects were more pronounced among men younger than 65 years and in those with
intermediate-risk tumors [7]. By contrast, the Prostate Cancer Intervention Versus
Observation Trial (PIVOT), which randomized 731 men to treatment with RP or
observation between 1994 and 2002, found no significant differences in all-cause and
prostate cancer-mortality between groups at ten years of follow up. On sub-group
analysis, the PIVOT study found a possible survival benefit to RP in men with intermediate
and high-risk tumors only [8]. The generalizability of these studies is limited, however,
because they were conducted either completely or partially before the era of PSA
screening. Therefore, the cohorts are likely to be poorly representative of the relatively
healthier contemporary population of men diagnosed with prostate cancer.
A third study, the Prostate Testing for Cancer and Treatment (ProtecT) trial,
compared the long-term oncologic outcomes associated with radiotherapy, surgery, and
active surveillance among men diagnosed with PSA-detected prostate cancer. In this
study, 82,429 men 50 to 69 years of age were randomized to one of the three treatment
arms between 1999 and 2009, with a primary outcome of prostate cancer-specific
mortality at a median of 10 years follow-up. While the authors reported that surgery and
radiotherapy can reduce the risk of cancer progression and metastasis, they found no
significant difference in all-cause or disease-specific deaths between the three groups at
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the 10-year median follow-up [9]. These initial findings suggest that there may be minimal
benefit to treating prostate cancer within the first decade after diagnosis.
However, longer follow up studies in the SPCG-4 [10] and PIVOT [11] trials have
since revealed oncologic benefits associated with the surgical treatment of prostate
cancer. At a median follow-up time of 23 years, the authors of the SPCG-4 study
reaffirmed that the prostatectomy group had significantly lower rates of overall and
prostate cancer-specific mortality, as well as a lower risk of metastasis, when compared
to the watchful waiting group. At this longer follow-up time, the absolute benefit
associated with surgery increased by a factor of more than 2 for overall and prostate
cancer-specific mortality. In the PIVOT trial, surgery was associated with lower all-cause
mortality among the 249 patients with intermediate-risk disease at a median follow-up
time of 19.5 years (HR = 0.68. 95% CI: 0.50-0.92). This benefit to surgery was not found in
low- and high- risk groups at this time-point. Given the time delay between surgery and
oncologic outcome improvements, men with longer life expectancies are likely to benefit
the most from prostatectomy. It is therefore essential to consider the impact of this
treatment on patient quality of life in the years following surgery.
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Incontinence after Treatment of Prostate Cancer
It is well documented that each of the common primary therapies for localized
prostate cancer can detrimentally affect functional outcomes with a negative impact on
patient quality of life, including bowel, sexual, and urinary function. Persistent urinary
incontinence has an especially profound negative impact on patient quality of life, causing
emotional distress and restrictions to normal physical activity [12, 13]. As such, current
AUA guidelines stress the importance of treatment counseling that incorporates shared
decision making and considers patient goals and preferences as well as tumor
characteristics [14].
Despite an increasing understanding of the etiology of post-prostatectomy
incontinence and improvements in surgical technique, incontinence rates are still
substantial and vary widely between different studies [15]. The variation in reported
continence outcomes stems, in part, from the lack of standardization in the definition of
continence. The most common definition of continence in the literature is patientreported use of 0 urinary pads per day (ppd) or a single safety liner, while others have
favored a stricter definition of absolutely no pad usage. A common method to further
quantify the degree of urinary incontinence is to document the number of pads used per
day. However, several studies have brought the validity of this approach into question,
showing that patients may change their pads at different rates based on their individual
attitudes and preferences rather than the actual volume of urine leakage [16, 17].
Measurement of pad weight to more accurately assess urine leakage has been employed
by some studies, but this method is impractical for large-scale studies. Finally,
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standardized questionnaires, such as the International Continence Society Male ShortForm (ICSmaleSF) questionnaire [18, 19], the Expanded Prostate Cancer Index Composite
(EPIC) instrument [20, 21], the International Consultation on Incontinence Questionnaire
(ICIQ) [22, 23], and International Prostate Symptom Score (IPSS) [24] are commonly used
to evaluate urinary function and impact on quality of life.
Data on patient-reported functional outcomes from the ProtecT trial, which
incorporated both measurements of pad count and some of the validated questionnaires
listed above, demonstrated that RP had a greater negative effect on urinary continence
than RT and active surveillance [25]. By year 6 of the study, 17% of men in the RP group
were using pads, compared to 8% in the active-monitoring group and 4% in the RT group.
The impact of urinary continence on quality of life was worse in the RP group for 2 years,
and subsequently became comparable to the other groups. In addition, a large,
population-based analysis reported that 6% of men treated with RP had undergone at
least 1 procedure to treat post-prostatectomy incontinence, such as urethral sling or
artificial urinary sphincter placement, by a median of 20 months after surgery [26].
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The Evolution of the Radical Prostatectomy
First performed over a century ago, the RP was traditionally performed via an
open, retropubic approach [27]. Over time, several innovations have been developed to
improve outcomes toward the RP “trifecta”: resection of malignant tissue with negative
surgical margins, preservation of urinary continence, and avoidance of erectile
dysfunction [28].
The introduction of the Da Vinci surgical system in 2001 prompted a shift from the
open RP to a robot-assisted laparoscopic approach (RALP). The enhanced visual field and
seven-degree motion provided by the robotic instruments offered the advantage of
precise identification of the fascial layers surrounding the prostate. This technology was
rapidly adopted despite the absence of conclusive evidence supporting its superiority at
the time, and as of 2015, nearly 70% of radical prostatectomies were performed
robotically in the United States [29]. In the past two decades, studies comparing the two
approaches have generally concluded that RALP leads to better peri-operative and longterm functional outcomes, without compromising oncological outcomes.
Guazzoni et al. [30] performed a prospective, randomized, single-surgeon study
comparing intra- and peri-operative outcomes between open RP and laparoscopic RP
(LRP), concluding that LRP offers the potential advantages of reduced blood loss, safe
early catheter removal, and possibly lower rates of analgesic use. The authors reported
no difference in post-operative complications and positive surgical margins (PSM)
between groups. In a randomized controlled trial (RCT) comparing early outcomes in 326
patients receiving RALP or open RP, Yaxley et al. [31] did not find significant differences
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in oncologic outcomes (positive surgical margin rate) or post-operative complications, nor
did they detect any significant differences in urinary and sexual function outcomes
between the groups at 6- and 12-weeks post-surgery. Two-year results from the same
cohort [32] confirmed the similar functional outcomes between groups, as determined
by the urinary and sexual domains of the EPIC questionnaire.
Results from three meta-analyses [33-35] comparing RALP and open RP found that
the robotic approach had better intra- and peri-operative outcomes, including estimated
blood loss (EBL), transfusion rates, overall complication rate, and duration of hospital
stay. Neither Cao et al. [35] nor Basiri et al. [34] found significant differences in oncological
or functional outcomes at time points of up to 24 months. Tang et al. [33] found higher
12- month rates of erectile function recovery after RALP (OR: 2.37, p = 0.005) compared
to open RP, but failed to find a significant difference with respect to urinary continence.
A more recent innovation to the surgical treatment of prostate cancer is the
Retzius sparing approach to RALP (RS-RALP), which preserves several structures thought
to play a role in urinary continence. First described by Galfano et al. in 2010, this approach
passes through the pouch of Douglas, following an intrafascial plane and avoiding
dissection of the anterior compartment, which contains endopelvic fascia, neurovascular
bundles, puboprostatic ligaments, and the prostatic venous plexus [36]. Dissection of the
bladder neck proceeds in a posterior-to-anterior fashion, preserving the integrity of the
detrusor apron at the bladder neck.
An early report of the first 200 patients to undergo RS-RALP demonstrated
excellent short-term urinary continence outcomes [37]. Within 7 days of catheter
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removal, 90-92% of patients were continent, defined as no pads or one safety liner per
day. At 1-year follow-up, the continence rate reached 100%. The patients in this cohort
were primarily low to intermediate risk (96% with Gleason score ≤ 7), with relatively small
prostates (median prostate volume 43 mL, interquartile range 28-58 mL). Finally, while
89-92% of patients achieved biochemical disease-free survival at one-year follow-up, the
authors note that the overall PSM rate was 25.5%.
Two randomized, single surgeon trials comparing RS-RALP and the standard
approach suggested that RS-RALP may provide superior short-term continence outcomes
[38, 39]. Menon et al. randomized 120 patients with clinically low-intermediate risk
disease to RS-RALP or traditional RALP. While the authors demonstrated significantly
higher rates of continence in the RS-RALP group at 3 months, these differences were
muted by 1 year after surgery. The PSM rate was noted to be higher in the RS-RALP group,
though the difference was not significant (11.7% vs. 8.3%, p > 0.05). Asimakopoulos et al.
also showed superior continence outcomes (defined as 0 ppd, no safety liner) in the RSRALP group up to 6 months after surgery, but longer-term data was not available. More
recently, Qiu et al. [40] performed a randomized, controlled, single-blind study
demonstrating higher rates of immediate continence (pad-free within 1 week after
catheter removal) in the RS-RALP group compared to traditional RALP (69.1% vs. 30.9%,
p = 0.000). Continence outcomes were also better in the RS-RALP group at 1 year (HR=
1.51, log-rank p = 0.007), though on sub-group analysis this applied only to patients with
low-intermediate risk disease. Oncologic outcomes, including PSM rate, were comparable
between the two groups.

10
Taken together, these studies provide initial evidence that RS-RALP provides
swifter return of continence compared to the traditional approach, but further studies
are needed to determine whether these differences remain significant at time points up
to a year after surgery. They also highlight the importance of appropriate selection of
patients for this procedure, given that there is some evidence of higher PSM rates with
this technique, particularly in higher risk patients. This potential drawback of RS-RALP
follows directly from its 360° intrafascial dissection of the prostate, which preserves key
surrounding structures as described above but also risks incomplete tumor resection,
particularly in cases where the tumor is located peripherally in the gland.
Another aspect of the surgical technique to consider is preservation of the
neurovascular bundle (NVB). Walsh et al. first described the posterolateral location of the
NVB relative to the prostate, its relevance to erectile function, and the nerve sparing (NS)
technique to improve post-operative erectile function [41, 42]. The relevance of NS
approach to preservation of urinary continence has subsequently been recognized [43].
Michl et al. provided insight into the possible mechanism of improved long-term
continence rates with NS RP [44]. They retrospectively analyzed patients who underwent
NS and non-nerve sparing (NNS) procedures, as well as a third group who had a secondary
resection of the NVBs for positive frozen-section results after initial NS dissection
(secNNS). Interestingly, they demonstrated increased post-operative continence rates at
1 week, 3 months, and 1 year both among patients in the NS and secNNS groups
compared to the NNS group. Continence rates at 1 year did not differ significantly
between the NS and secNNS groups (85.4% vs. 87.0%; p = 0.5). The authors concluded
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that the meticulous apical dissection involved in the NS approach, and not the actual
preservation of the NVBs, accounted for the improved continence outcomes in this group.

Patient Characteristics Influencing Return of Continence
Previous studies have found that certain pre-operative patient characteristics also
influence post-operative return of continence, including age, body mass index (BMI),
comorbidity index, membranous urethral length (MUL), prostate volume, and lower
urinary tract symptoms (LUTS) [15, 45].
Several studies have examined the effect of age on functional outcomes after
radical prostatectomy. In a large retrospective study, Mandel et al. [46] stratified patients
who underwent open RP or RALP into age groups of <65, ≥65 and <70, ≥70 and <75, and
≥75, and showed that continence outcomes (defined as 0-1 ppd) at 3 months (80.3%,
74.0%, 70.3%, and 66.1%, p < 0.001) and 1 year (93.3%, 90.8%, 86.0%, and 86.5%, p <
0.001) after surgery decreased significantly with increasing age at the time of surgery. It
is interesting to note that, although there was a significant difference across age groups
in continence rates at both time points, the difference narrowed at 1 year, suggesting that
older men who ultimately achieve continence may simply take longer to do so. Similarly,
Kundu et al. [47] found significant differences in rates of return of continence (defined as
no pads) for patients aged <50, 50-59, 60-69, and ≥70 years (95%, 96%, 93%, and 86%,
respectively, p < 0.001) among men who underwent open RP. In contrast, Kunz et al. [48]
reported an insignificant difference in continence at 24 months (2.01 vs. 2.10, p = 0.98)
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between patients aged <70 (n = 1,225) and ≥70 (n = 411), using ICSmaleSF questionnaire
scores to quantify the degree of continence.
Studies including only RALP procedures have also yielded mixed results with
respect to the effect of age on continence. Shikanov et al. [49] demonstrated a significant
influence of age on the probability of achieving continence at 12 months (OR = 0.97, p =
0.002) among 1,436 men who underwent RALP. Basto et al. [50] stratified 262 men who
underwent RALP into two groups (age <70 and ≥70 years). While they found a trend
toward fewer older men being fully continent (no pads) at 4-6 weeks, there were no
differences between the groups beyond 3 months. Similarly, Greco et al. [51] performed
a single-surgeon retrospective analysis of men who underwent RALP and found that
continence (no pads) was significantly lower in men ≥70 years at 6 months after surgery
but returned to levels equivalent to those in younger men by 1 year. Finally, in a larger
study of 2,000 RALP patients, Labanaris et al. [52] did not find a significant difference in
the 12-month continence rate (no pads) between groups aged <75 and ≥75 years (92.8%
vs. 86.9%, p > 0.05).
Membranous urethral length (MUL), the distance from the prostatic apex to the
level of the urethra at the penile bulb, has also been reported to affect postprostatectomy return of continence. This value can be measured pre-operatively on T2weighted magnetic resonance imaging (MRI) images. A meta-analysis of studies
examining this anatomical factor concluded that MUL had a significant positive effect on
the odds of continence recovery at 3-, 6-, and 12-months following surgery [53]. The
authors calculated that for every extra millimeter of MUL, the estimated odds of
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continence recovery increased by 5-15% (OR: 1.09, 95% CI:1.05-1.15; p < 0.001). A recent
retrospective study by Ikarashi et al. examined the effect of MUL on continence recovery
after RALP [54]. The authors estimated a cutoff point for using MUL to predict return of
continence at 3 months after surgery using a receiver operating characteristic (ROC)
analysis. They found that using a cutoff point of 12 mm MUL could predict continence at
3 months with 80% sensitivity and 70% specificity.
Prostate volume (or weight) is another anatomical characteristic that may affect
continence outcomes, although conflicting evidence exists in the literature. Mandel et al.
performed a retrospective study of 5,477 patients who underwent RP and found that
large prostate volume (>70 mL) negatively impacted post-operative return of continence,
particularly at early (1-week and 3-month) time points [55]. Several other investigators
have found similar results regarding the impact of prostate volume on post-operative
continence, both in patients receiving open RP and RALP [56-58]. More recently, Galfano
et al. investigated the effect of prostate volume on continence specifically after RS-RALP
[59]. They evaluated 750 patients with small (<40 g), medium (40-60 g), and large (>60 g)
prostates who underwent RS-RALP and found significant differences in the immediate
continence rate between groups (88%, 89.5%, 81.3%; p = 0.045). However, no differences
were observed between the groups after 1 year (93.4%, 94.1%, 94.7%; p = 0.892).
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PURPOSE

The purpose of this study is to identify the degree to which pre-operative patient
factors, tumor characteristics, and surgical technique influenced the post-operative
return of urinary continence in men undergoing RALP performed by a single surgeon for
the treatment of clinically localized prostate cancer.
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METHODS

Patient Population
Between April 2013 and September 2020, 182 men undergoing robotic-assisted
laparoscopic prostatectomy (RALP) by a single urologist for clinically localized or locally
advanced prostate cancer at our institution (Yale-New Haven Hospital) were included in
the final analysis, after exclusion criteria were applied.

Surgical Procedure and Pathology
RALP was performed using the multiple- or single-port da Vinci surgical robot
system (Intuitive Surgical, Sunnyvale, CA) via a transperitoneal or extraperitoneal
approach. Information on the details of the surgical technique were recorded, namely the
presence of pelvic lymph node dissection (PLND), complete or partial nerve sparing, and
Retzius sparing approach. Patients without contraindications underwent pelvic MRI preoperatively. Pathological staging, Gleason score, Grade Group, presence of metastatic
lymph nodes, and prostate weight were determined by a board-certified pathologist from
whole mount surgical specimens. and retrospectively documented based on pathology
reports.

Evaluation of Pre-operative Patient Characteristics and Surgical Approach
Age at the time of surgery, body mass index (BMI), type of surgical approach
(nerve sparing, Retzius sparing), preoperative PSA, and serum testosterone level were
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retrospectively collected from patient charts. Prostate volume was estimated on preoperative pelvic MRI by a board-certified radiologist and extracted from image reports.
MUL was retrospectively measured on T2-weighted coronal and sagittal sections as the
distance from the prostatic apex to the level of the urethra at the penile bulb on preoperative pelvic MRI. Measurements from the coronal and sagittal sections were
averaged for the final estimate of MUL.

Evaluation of Post-operative Urinary Continence
Post-operative recovery of urinary continence was defined as patient-reported
use of 0 ppd or an occasional safety liner, as documented in notes from routine postoperative clinic visits. Achievement of continence was defined as early if it occurred within
3 months, and late if it occurred within 12 months after the date of surgery. Catheter
removal occurred one week after the date of surgery in most cases. Two patients in our
cohort required prolonged catheterization longer than one week due to post-operative
complications (1 urine leak, 1 urinary fistula). Patients who underwent salvage RT were
excluded from our analysis starting at the date of RT initiation.

Statistical Methods
Kruskal–Wallis test was used for statistical analysis of proportions, and the MannWhitney U test was used for continuous variables. Univariable and multivariable logistic
regression and ROC curves were used to assess discriminatory ability of membranous
urethral length to predict continence following prostatectomy. Two-sided p values <0.05
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were statistically significant. SPSS version 27 (IBM SPSS Statistics, Armonk, NY, USA) was
utilized to conduct the analysis.
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RESULTS

Patient Characteristics and Surgical Approach
We identified a total of 187 patients who underwent radical prostatectomy for the
treatment of clinically localized or locally advanced prostate cancer, performed by a single
surgeon at our institution between 2013 and 2020. Four patients were excluded from our
analysis because the surgical procedure was performed via an open retropubic approach,
rather than RALP. Thirty-one patients underwent salvage RT within one year after surgery
and were therefore excluded from our analysis at the 12-month timepoint to avoid
confounding effects on continence outcomes from radiation exposure. One patient
underwent RT within three months after surgery and was therefore excluded from both
the 3- and 12-month timepoints. The remaining 30 patients who underwent RT between
3 and 12 months were excluded from the 12-month analysis. The final number of included
patients was therefore 182 at the 3-month timepoint, and 152 at the 12-month timepoint.
Clinical characteristics of the patients included in the study, as well as details on the
surgical approach used, are shown in Table 1. Mean patient age was 62.4 ± 6.4 years,
mean BMI was 28.6 ± 4.4 kg/m2, mean pre-operative PSA was 11.8 ± 16.7 ng/mL, mean
prostate weight was 49.4 ± 25.5 g, and mean MUL was 13.7 ± 3.4 mm. All patients included
in our analysis were continent prior to surgery. All patients included in our analysis
underwent RALP with bilateral pelvic lymph node dissection (BPLND). 57 (31%) patients
underwent a complete nerve sparing procedure, 79 (43%) patients underwent a partial
nerve sparing procedure, and 46 (25%) underwent a non-nerve sparing procedure.
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Retzius sparing was performed in 43 (24%) patients, and a single port procedure was
performed in 11 (6%) patients.
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Table 1. Patient Characteristics and Details of Surgical Approach
Age (years)
Mean ± SD

62.4 ± 6.4

Min - Max

41.2 - 76.7

No. (%) <60

55 (30%)

No. (%) ≥60 and <65

53 (29%)

No. (%) ≥65 and <70

50 (28%)

No. (%) ≥70

24 (13%)

Mean ± SD

28.6 ± 4.4

Min - Max

20.1 - 44.9

BMI (kg/m²)

Pathological Stage

Patient
Characteristics

No. (%) Stage II

78 (43%)

No. (%) Stage III

95 (40%)

No. (%) Stage IV

31 (17%)

Grade Group (Surgical Pathology)
No. (%) GG 1

3 (2%)

No. (%) GG 2

109 (60%)

No. (%) GG 3

49 (27%)

No. (%) GG ≥4

19 (10%)
1

No. (%) Unassigned

2 (1%)

Pre-operative PSA (ng/mL)
Mean ± SD

11.8 ± 16.7

Min - Max

0.1 - 137

Mean ± SD

49.4 ± 25.5

Prostate weight (g)
Min-Max

14 - 182

MUL (average)

Surgical
approach

Mean ± SD

13.7 ± 3.4

Min-Max

6.4 - 23.3

Non-nerve sparing

No. (%)

46 (25%)

Partial nerve sparing

No. (%)

79 (43%)

Complete nerve sparing

No. (%)

57 (31%)

Non-Retzius sparing

No. (%)

139 (76%)

Retzius sparing

No. (%)

43 (24%)

Single Port
No. (%)
11 (6%)
By convention, a Gleason score is not assigned to patients who received androgen deprivation therapy
(ADT) prior to radical prostatectomy.
1
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Early Recovery of Continence
Early recovery of urinary continence, defined as continence at 3 months after
surgery, was achieved in 68 (37.4%) patients. In the univariate analysis for early recovery
of continence, lower BMI (27.6 kg/m2 vs. 29.1 kg/m2, p = 0.014), lower prostate weight
(43.0 g vs. 52.0 g, p = 0.003), and the Retzius sparing approach (60.9% vs. 29.3%, p < 0.001)
were significantly associated with continence at this timepoint. Results from the
multivariate analysis for early recovery of continence are shown in Table 2. BMI (OR 0.902
per kg/m2; 95% CI 0.823 – 0.988; p = 0.027) and Retzius sparing surgery (OR 2.995; 95%
CI 1.265 – 7.089; p = 0.013) were shown to be significantly and independently associated
with continence by 3 months. Prostate weight (OR 0.992; 95% CI 0.971 – 1.013; p = 0.436)
was found to be non-significant on multivariate analysis.
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Table 2. Multivariate analysis results for the early (3-month) recovery of urinary
continence. Significant values are denoted in bold.

Variable

p value

Odds Ratio (OR)

95% C.I. for OR

Age (years)

0.159

0.955

0.897 – 1.018

BMI (kg/m2)

0.027*

0.902

0.823 – 0.988

Prostate weight (g)

0.436

0.992

0.971 – 1.013

MUL (mm)

0.094

1.110

0.982 – 1.255

Non-nerve Sparing (ref)

0.614

Unilateral nerve sparing

0.327

1.724

0.581 – 5.117

Bilateral nerve sparing

0.422

1.606

0.506 – 5.097

Retzius sparing

0.013*

2.995

1.265 – 7.089

Late Recovery of Continence
Late recovery of urinary continence, defined as continence at 12 months after
surgery, was achieved in 120 (78.9%) patients. In the univariate analysis, younger age at
the time of surgery (61.7 years vs. 65.0 years, p = 0.004) was significantly associated with
continence at this time point. The 12-month continence rates for age groups < 60, ≥ 60
and < 65, ≥ 65 and < 70, and ≥ 70 years were 89.3%, 73.8%, 66.0%, and 66.7%, respectively
(p = 0.053). On multivariate analysis, MUL (OR 1.205 per mm; 95% CI 1.003 – 1.448; p =
0.047) and age at the time of surgery (OR 0.907 per year; 95% CI 0.824 – 0.998; p = 0.044)
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were shown to be significantly and independently associated with continence at 12
months post-operatively. Results from the analysis are shown in Table 3.
As previously noted, 30 patients included in the 3-month analysis were
subsequently excluded at this timepoint due to initiation of salvage radiotherapy within
1 year after surgery. Among this subset of patients, 20 (66.7%) achieved continence prior
to the initiation of radiotherapy. Furthermore, a total of 22 (73.3%) of these patients
achieved continence within a year after RALP.

Table 3. Multivariate analysis for the late (12-month) recovery of urinary continence.
Significant values are denoted in bold.

Variable

p value

Odds Ratio (OR)

95% C.I. for OR

Age (years)

0.044*

0.907

0.824 – 0.998

BMI (kg/m2)

0.381

1.057

0.933 – 1.198

Prostate weight (g)

0.225

0.985

0.960 – 1.010

MUL (mm)

0.047*

1.205

1.003 – 1.448

Non-nerve Sparing (ref)

0.128

Unilateral nerve sparing

0.321

0.540

0.160 – 1.824

Bilateral nerve sparing

0.384

1.876

0.455 – 7.741

Retzius sparing

0.428

1.624

0.490 – 5.383
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The receiver operating characteristic (ROC) curve for MUL measurement as a
predictor of continence at 12 months is shown in Figure 1. The area under the curve (AUC)
was 0.60. We identified a reasonable cutoff point of MUL > 10.6 mm for recovery of
continence at 12 months using the ROC analysis. Using this cutoff point, we were able to
predict continence at 12 months after RALP with a sensitivity of 85% and a specificity of
43%.

Figure 1. ROC curve for recovery of urinary continence at 12 months after RALP.
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DISCUSSION

This study demonstrates that early recovery of continence after RALP is primarily
associated with lower BMI and Retzius sparing approach, while younger age and longer
pre-operative MUL are the strongest predictors of the return of continence at 12 months
post-operatively. The overall rates of continence recovery for the patients in this cohort
were 37.3% at 3 months and 78.9% at 12 months. As previously noted, post-operative
continence rates vary widely in the literature. The 2012 meta-analysis performed by
Ficarra et al. [15] reported 12-month continence rates ranging from 69% to 96%, with a
mean value of 84% using a no pad definition. Considering a no pad or safety pad
definition, as was done in this study, the authors noted a narrower range of 89% to 92%,
with a mean value of 91% at 12 months.
The Retzius sparing approach was strongly associated with continence at the 3month timepoint, however this association disappeared at the 12-month timepoint. This
result is in line with data from a number of similar studies, including the Menon et al.
study [38] cited previously, which also found a significant effect at 3 months that was
subsequently muted by 12 months post-operatively. In our study at 3 months, the overall
continence rate among patients who underwent RS-RALP was 60.9% versus 29.3% among
those who underwent conventional RALP. Menon et al. achieved a 3-month continence
rate of 95% with the Retzius sparing approach versus 86% with conventional RALP. These
remarkably high values may be partially explained by their cohort, which consisted of
younger, less obese men with overall lower stage pathology when compared to our
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cohort, and also surgeon experience. Nevertheless, our results highlight the relative
efficacy of the Retzius sparing approach with respect to achieving earlier restoration of
continence, without necessarily affecting long term outcomes. As previously discussed,
the mechanistic explanation for earlier continence using this approach is related to better
preservation of the bladder neck and structures in the space of Retzius. Further studies
with larger scale cohorts are needed to definitively show whether the advantage of this
approach truly does not extend past the first 3 to 6 months after surgery.
Similarly, lower BMI was also predictive of higher rates of continence at 3 months
after RALP, but this effect was not seen at 1 year post-operatively. This finding is
consistent with a 2015 study by Matsushita et al. [60] that examined 2,849 radical
prostatectomies to identify predictors of continence. The authors reported that BMI was
associated with urinary continence at 6 months (OR 0.97; p = 0.01), but not at 12 months
(p = 0.1). As noted previously, Mandel et al. [46] performed a large study on over 8,000
patients who underwent radical prostatectomy. They showed that BMI was significantly
associated with urinary continence at both 3 months (OR 0.97; 95% CI 0.94 – 0.99; p =
0.002) and 12 months (OR 0.96; 95% CI 0.94 – 0.99; p = 0.013).
When considering the results of our study at 3 versus 12 months after RALP, it
should be noted that the later timepoint carried somewhat less power than the earlier
timepoint due to our exclusion criteria, which included initiation of salvage radiotherapy.
Because we excluded patients from our analysis at the time of salvage therapy initiation,
30 patients were excluded from the 12-month analysis after undergoing radiation
between 3 months and 1 year post-operatively. Consequently, it’s possible that this
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attrition partially explains the loss of the significant associations of BMI and RS-RALP with
continence between the two timepoints. Among this subset, 20 (66.7%) achieved
continence prior to the initiation of salvage radiotherapy, and 22 (73.3%) were continent
within a year after surgery. Therefore, while not included in the final analysis, the
continence rates in this subset were similar to the larger cohort.
Our analysis showed that younger age was significantly associated with higher
rates of continence at one year after RALP. However, this association was not seen at 3
months. There was a trend toward increasing continence rates at 12 months across age
groups < 60, ≥ 60 and < 65, ≥ 65 and < 70, and ≥ 70 years (89.3%, 73.8%, 66.0%, and 66.7%;
p = 0.053). As discussed previously, Mandel et al. [46] also found that continence rates
decreased significantly with increasing age. The 12-month continence rates for age
groups < 65, ≥ 65 and < 70, ≥ 70 and < 75, and ≥ 75 years were 93.2%, 90.8%, 86.0%, and
86.5%, respectively. It should be noted that this study’s cohort was slightly older than
ours (mean age 63.9 years), it stratified patients into different age groups than our study,
and it included both open and robotic prostatectomies.
Our results also agree with the Shikanov et al. study [49], which included only
robotic procedures. They found that increasing age was associated with decreasing 1-year
continence rates (OR 0.92; p < 0.0001), which closely matched our results. However, their
overall continence rates were somewhat lower due to their use of a stricter (no pad)
definition of continence. Interestingly, both Basto et al. [50] and Greco et al. [51] found
that younger age was associated with higher continence rates at earlier time points, but
this effect did not extend to 1 year after RALP. Our results show the opposite pattern,
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with differences in continence between age groups becoming significant only at the 12month timepoint.
Longer pre-operative MUL was also shown to be predictive of continence at 12
months after surgery, with an OR of 1.205 per millimeter (p=0.047). As previously noted,
the meta-analysis conducted by Mungovan et al. [53] yielded similar results. The authors
examined 11 studies that reported the OR for restoration of continence at one or more
time points and found that MUL had a significantly positive effect on continence at 12
months (OR: 1.12, 95% CI: 1.03–1.22, p = 0.006). In contrast to our results, they also found
significant associations of a similar magnitude between MUL and continence at 3 and 6
months. Similarly, the Ikarashi et al. study [54] found a significant association between
MUL and lower rates of incontinence at 3 (OR 0.635; 95% CI 0.53 – 0.74; p < 0.0001), 6
(OR 0.699; 95% CI 0.56 – 0.85; p = 0.0002), and 12 (OR 0.743; 95% CI 0.56 – 0.96; p =
0.026) months.
This association is thought to stem from the coordinated function of the smooth
muscle fibers within the membranous urethra and the rhabdosphincter that surrounds it,
which plays a key role in preventing urinary leakage. Increased MUL is therefore related
to a greater number of these muscular components that increase urethral closure
pressure that aid in recovery of continence. Paparel et al. [61] showed this with pre- and
post-operative measurements of MUL, showing that decreased length of MUL after
surgery also predicts incontinence. The authors also suggested that limiting intraoperative trauma to membranous urethra, and therefore peri-urethral fibrosis and

29
decreased elasticity of the external urinary sphincter, is important to the preservation of
continence.
After establishing the association between MUL and the late recovery of
continence, we constructed an ROC curve to evaluate the predictive ability of this
measurement and identify a reasonable cutoff point for favorable prediction of
continence at 12 months after RALP. The results of the ROC analysis yielded a proposed
cutoff point of 11 mm, which predicted 12-month recovery of continence with 85%
sensitivity. However, the specificity was considerably lower at 43%, which limits its utility
as an accurate predictive tool. Comparing these results to the Ikarashi et al. study [54],
the authors identified a cutoff point of 12 mm for continence at 3 months, yielding an
80% sensitivity and 70% specificity.
There are several limitations which may have influenced the validity of this study’s
results. First, the retrospective design of the study introduced several sources of bias.
Most notably, some patient records were missing or incomplete, especially with respect
to consistent documentation of patient pad count in post-operative clinic notes. A
prospective study with a standardized method of collecting pad count data or the use of
a validated incontinence questionnaire would be a more reliable method of evaluating
urinary continence outcomes. Furthermore, even among patients with complete records,
self-reported pad count is an inherently imperfect measure of incontinence due to recall
bias, different activity levels between patients requiring different needs for protection
against urinary leakage, and different patient preferences with respect to their tolerance
for urinary leakage and therefore the number of pad changes per day. Another key
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limitation of the study is its relatively small size (N=182), which limits the study’s power.
Finally, the study’s single-surgeon design may limit the ability to generalize the results to
the entire population of men undergoing RALP.
In summary, these results add to the existing literature examining the factors,
related to both pre-operative patient characteristics and surgical technique, that affect
the probability of a patient recovering urinary continence in their first year after RALP.
Identifying the relative importance of these influences on continence is critical to the
appropriate counseling of patients considering their treatment options for prostate
cancer. An understanding of the primary risk factors for post-operative incontinence
presented here and elsewhere in the literature, combined with a firm understanding of
each patient’s specific goals and expectations, will allow physicians to provide better
guidance to patients as they navigate these difficult decisions.
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